Sodium-Glucose Cotransporter-2 Inhibitors and Cutaneous Adverse Reactions: A Systematic Review of Clinical Phenotypes, Time-to- Onset Profiles, and Management Strategies (2020–2026)
This systematic review of 42 studies (2020–2026) characterizes the diverse spectrum of SGLT2 inhibitor-induced cutaneous adverse reactions, distinguishing between early-onset mild eruptions manageable with symptomatic treatment and delayed-onset severe immune-mediated or necrotizing conditions that require drug withdrawal and multidisciplinary intervention.